Stocktoria
NRX Pharmaceuticals, Inc. NRXP
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2017-11-20
NRX Pharmaceuticals, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2023 | FY2023 |
|---|---|---|---|---|---|
| Revenue | $1.4M | $0 | $0 | — | — |
| R&D expense | $3.8M | $6.2M | $13.4M | — | — |
| SG&A expense | $13.1M | $13.5M | — | — | — |
| Operating income | -$16.2M | -$18.5M | -$27.8M | — | — |
| Interest expense | — | — | $120,000 | — | — |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$28.6M | -$25.1M | -$30.1M | — | — |
| Operating cash flow | -$14.1M | -$10.6M | -$21.7M | — | — |
| Cash & equivalents | $7.8M | $1.4M | $4.6M | $8.9M | $15.0M |
| Total assets | $13.0M | $3.7M | $7.3M | $13.1M | $19.8M |
| Total liabilities | $28.9M | $26.9M | $19.0M | $19.3M | $22.6M |
| Shareholders' equity | -$15.9M | -$23.2M | -$11.7M | -$6.2M | -$2.8M |
Source: SEC EDGAR filings · CIK 0001719406 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.